Suppr超能文献

在肝细胞癌患者中,与单纯肝切除术相比,术前使用乐伐替尼联合抗PD-1抗体进行全身治疗后肝切除术的安全性概况。

The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma.

作者信息

Shen Ying-Hao, Huang Cheng, Zhu Xiao-Dong, Xu Ming-Hao, Chen Zhao-Shuo, Tan Chang-Jun, Zhou Jian, Fan Jia, Sun Hui-Chuan

机构信息

From the Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.

Department of Hepatobiliary Pancreatic Surgery, Fujian Medical University Cancer Hospital, Fuzhou, China.

出版信息

Ann Surg Open. 2022 May 2;3(2):e163. doi: 10.1097/AS9.0000000000000163. eCollection 2022 Jun.

Abstract

OBJECTIVE

To determine the safety of hepatectomy after combined lenvatinib and anti-PD-1 preoperative systemic therapy (PST) in patients with marginally resectable hepatocellular carcinoma (HCC).

BACKGROUND

PST followed by hepatectomy (PSTH) is an emerging treatment for HCC. However, the impact of PST with lenvatinib plus anti-PD-1 antibodies on surgical safety is unknown.

METHODS

Medical records from consecutive patients with marginally resectable advanced HCC who underwent hepatectomy after PST with lenvatinib and anti-PD-1 antibodies between January 2018 and August 2021 were retrieved from a prospectively designed database. Propensity score matching (1:2) was performed with a further 2318 HCC patients who underwent upfront hepatectomy (UH) without initial antitumor treatment during the same period.

RESULTS

In total, 49 and 98 matched patients were included in the PSTH and UH groups, respectively. Compared to the UH group, individuals in the PSTH group experienced more intraoperative blood loss, blood transfusions, and longer postoperative hospital stays. Moreover, posthepatectomy liver failure was more common in the PSTH group, who also had worse albumin-bilirubin (ALBI) scores on postoperative days 1-7. A significantly greater amount of drainage was also required in the PSTH group. However, the 30-day morbidity and 90-day mortality were similar among the two groups. Additionally, the duration of surgery, use of hepatic inflow occlusion during surgery, and the levels of postoperative inflammation-based markers were not statistically different between the two groups.

CONCLUSIONS

Despite more intraoperative and postoperative adverse events, PSTH had comparable 30-day morbidity and 90-day mortality as UH. Thus, PSTH appears to be a viable treatment option for marginally resectable HCC patients with careful preoperative evaluation.

摘要

目的

确定在边缘可切除的肝细胞癌(HCC)患者中,乐伐替尼与抗程序性死亡蛋白1(PD-1)术前全身治疗(PST)联合应用后进行肝切除术的安全性。

背景

PST后行肝切除术(PSTH)是一种新兴的HCC治疗方法。然而,乐伐替尼联合抗PD-1抗体的PST对手术安全性的影响尚不清楚。

方法

从一个前瞻性设计的数据库中检索2018年1月至2021年8月期间接受乐伐替尼和抗PD-1抗体PST后行肝切除术的连续边缘可切除晚期HCC患者的病历。对另外2318例同期接受 upfront肝切除术(UH)且未进行初始抗肿瘤治疗的HCC患者进行倾向评分匹配(1:2)。

结果

PSTH组和UH组分别纳入49例和98例匹配患者。与UH组相比,PSTH组患者术中失血更多、输血更多,术后住院时间更长。此外,肝切除术后肝衰竭在PSTH组更常见,且术后1-7天白蛋白-胆红素(ALBI)评分更差。PSTH组的引流量也明显更多。然而,两组的30天发病率和90天死亡率相似。此外,两组之间的手术时间、手术中肝血流阻断的使用情况以及术后炎症指标水平无统计学差异。

结论

尽管有更多的术中和术后不良事件,但PSTH的30天发病率和90天死亡率与UH相当。因此,对于边缘可切除的HCC患者,经过仔细的术前评估,PSTH似乎是一种可行的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5204/10431521/5f85ac80cf30/as9-3-e163-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验